DZS Supported Clinical Study of 5-ALA SFC in Middle East

DZS supported clinical study in Middle East recently published in the Journal of Diabetes Research

DZS supported one of the first pharmaceutical sponsored clinical research studies entirely performed in the Kingdom of Bahrain. The study of 5-ALA SFC, sponsored by SBI Pharmaceuticals, was recently published in a local journal.
This pilot trial studied the safety and efficacy of the nutritional supplement, 5-ALA SFC, in patients with type 2 diabetes mellitus.  Considering very few trials have been performed in Bahrain and the prevalence of type 2 diabetes is rapidly increasing, the study results were eagerly anticipated. 
Operationally, the study posed some unique challenges, including relatively inexperienced sites and oversight boards.  SBI and DZS developed various techniques to assist the sites including intensive training, frequent teleconferences, and daily communications with Sponsor representatives.  DZS is proud of the role it played to assist the Sponsor in executing the trial and the resulting publication in The Journal of Diabetes Research.  We continue to work in the region and have recently expanded our site identification and monitoring capabilities to Jordan.
Image: jk1991 / 123RF Stock Photo